lambert therapeutics

Natural product-inspired therapeutics for brain health and longevity

Lambert Therapeutics is an early-stage biotechnology company spun out of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. We design non-intoxicating small molecules for conditions where existing drugs fall short.

See our programmes Partner with us
Lambert Therapeutics
10 years
of philanthropically funded cannabinoid science behind the company
200+
peer-reviewed publications from the founding research programme
25+
completed clinical trials of medicinal cannabis products
1,250+
proprietary molecules in the discovery library
Programmes

Three indications, one chemistry platform

A portfolio approach across chemically distinct series, chosen where the unmet need is large and the regulatory path is well established.

A child receiving an oral medicine, with the brain illustrated
Drug-resistant epilepsy

Next-generation anti-seizure therapy

Epilepsy affects around 70 million people worldwide, and roughly a third do not respond to existing medications. The developmental and epileptic encephalopathies — Dravet and Lennox-Gastaut syndromes among them — remain severely undertreated in children.

Cannabidiol proved the mechanism is real but carries practical limits: low oral bioavailability, variable exposure, liver signals and drug–drug interactions. Our lead series was designed against exactly those liabilities, and shows anti-seizure activity in zebrafish and mouse models of Dravet syndrome without the sedation and motor impairment that limit current options.

  • Discovery
  • Lead selected
  • Preclinical validation
  • IND-enabling
  • Clinic
A person sleeping peacefully at night
Insomnia

A hypnotic without the hangover

Chronic insomnia affects 10–15% of adults, and a further third experience intermittent symptoms. It is an independent risk factor for depression, cardiovascular disease, type 2 diabetes and dementia — yet current drugs bring dependence, next-day sedation and cognitive cost, while cognitive behavioural therapy remains expensive and hard to access.

Screening hundreds of compounds through a 24-hour zebrafish circadian activity model surfaced a lead with an unusual pro-sleep signature. It increases NREM sleep in mice under EEG recording, and represents a new class of hypnotic agent.

  • Discovery
  • Lead optimisation
  • Preclinical validation
  • IND-enabling
  • Clinic
An older woman celebrating outdoors in good health
Healthy ageing

Gerotherapeutics from hemp-derived chemistry

Ageing is the dominant risk factor for more than 200 diseases. Treating each condition once it has arrived is treating it late; targeting ageing biology directly offers the prospect of delaying several at once.

Our gerotherapeutic candidates — both non-intoxicating hemp constituents and novel molecular entities derived from them — produce world-leading lifespan extension in C. elegans. In aged mice, eight months of daily oral dosing reduced frailty and shifted body composition toward lean mass, with improved metabolic flexibility. Companion-animal and pilot human studies are in design.

  • Discovery
  • Lead optimisation
  • Preclinical validation
  • IND-enabling
  • Clinic
Platform

How a molecule moves through us

High-throughput screening across four biological systems, run in state-of-the-art laboratories at the Brain and Mind Centre, University of Sydney.

01 / Chemistry

Structure-guided design

Analogues built around non-intoxicating cannabinoid scaffolds, optimised for CNS penetration, metabolic stability and clean interaction profiles. Best-in-class AI predictive tools aid target deconvolution.

02 / Invertebrate

C. elegans and zebrafish

Rapid lifespan, senescence and circadian-activity screens that let hundreds of compounds be ranked before any mammalian work begins.

03 / Rodent

Disease and healthspan models

Genetic and induced seizure models, EEG sleep architecture, rotarod and frailty indices, body composition and metabolic phenotyping.

04 / Developability

ADME, PK and safety

Bioavailability, brain penetration and clearance, alongside liver toxicity, hERG and drug–drug interaction screening ahead of IND-enabling studies.

Founders

Built by the people who did the science

Lambert Therapeutics was founded by three researchers from the Lambert Initiative, supported by the University of Sydney Commercialisation Office.

Co-founder

Prof Iain McGregor

  • Professor of Psychopharmacology
  • Academic Director, Lambert Initiative
  • Clinical trials expert, 25+ trials
  • 390+ publications; 70+ patents across multiple jurisdictions
iain@lamberttherapeutics.com
Co-founder

Prof Jonathon Arnold

  • Professor of Pharmacology
  • Preclinical epilepsy specialist
  • WHO advisor on cannabinoids; two ILAE awards
  • 150+ publications; lead inventor on recent filings
jonathon@lamberttherapeutics.com
Co-founder

Dr Muneer Ahamed

  • Drug discovery and product development
  • Serial co-inventor of new molecular entities
  • CNS and precision medicine background
  • Experienced in managing CRO relationships
muneer@lamberttherapeutics.com
Contact

We are talking to investors and partners

Lambert Therapeutics is raising to advance its lead programmes through non-GLP toxicology and ADME/PK studies. We are also interested in conversations about asset-level licensing and preclinical collaboration.

Enquiries info@lamberttherapeutics.com
Laboratories Brain and Mind Centre, Sydney
Research origin sydney.edu.au/lambert